A Study to Evaluate the Efficacy and Safety of BHV-2100 in Acute Migraine

This study is designed to identify at least one dose of BHV-2100 that is safe, well-tolerated, and effective in pain reduction and in achieving freedom from the most bothersome symptom (MBS) associated with migraine at 2 hours post-dose.

BHV-2100 is a new type of drug taken by mouth that blocks a specific receptor (a part of a nerve cell involved in receiving and sending signals) called TRPM3. This receptor is in nerve cells involved in signaling pain, which could include causing migraine symptoms. TRPM3 is found in parts of the nervous system that control inflammation and pain response. By blocking TRPM3, the drug may help calm down pain signals. Certain genetic changes in TRPM3 are linked to higher chances of migraines and sensitivity to pain. TRPM3 also influences other receptors related to pain, and early tests show that blocking these receptors may help treat migraines.